| First Author | Dewayani A | Year | 2022 |
| Journal | Biochem Biophys Res Commun | Volume | 613 |
| Pages | 26-33 | PubMed ID | 35526485 |
| Mgi Jnum | J:325131 | Mgi Id | MGI:7283733 |
| Doi | 10.1016/j.bbrc.2022.04.125 | Citation | Dewayani A, et al. (2022) TRAF6 signaling pathway in T cells regulates anti-tumor immunity through the activation of tumor specific Th9 cells and CTLs. Biochem Biophys Res Commun 613:26-33 |
| abstractText | CD8(+) cytotoxic T lymphocytes (CTLs) and CD4(+) helper T (Th) cells play a critical role in protective immune responses to tumor cells. Particularly, Th9 cells exert anti-tumor activity by producing IL-9. TNF receptor (TNFR)-associated factor 6 (TRAF6) is an adaptor protein that mediates the signals from both the TNFR superfamily and Toll-like receptors (TLRs). We have previously reported that T cell-specific TRAF6-deficent (TRAF6DeltaT) mice spontaneously developed systemic inflammatory diseases. However, the physiological role of TRAF6 in T cells in controlling anti-tumor immune responses remains largely unclear. Here, we found that tumor formation of syngeneic colon cancer cells inoculated in TRAF6DeltaT mice was accelerated compared to that in control mice. Although TRAF6-deficient naive T cells showed enhanced differentiation of Th9 cells in vitro, these T cells produced lower amounts of IL-9 in response to a specific antigen. Moreover, CD4(+) tumor-infiltrating lymphocytes (TILs) in tumor-bearing TRAF6DeltaT mice expressed lower levels of IL-9 than those in WT mice. Importantly, administration of recombinant IL-9 (rIL-9) strongly suppressed tumor progression in TRAF6DeltaT mice. Furthermore, expression levels of the T-box transcription factor Eomesodermin (Eomes) and its target molecules IFN-gamma, granzyme B and perforin, as well as cytotoxic activity, were reduced in TRAF6-deficient CD8(+) T cells in vitro. TRAF6-deficient T cells were found to express significantly increased levels of immune checkpoint molecules, CTLA-4 and PD-1 on the cell surface. These results demonstrate that the TRAF6 signaling pathway in T cells regulates anti-tumor immunity through the activation of tumor specific Th9 cells and CTLs in a tumor microenvironment. |
